Unknown

Dataset Information

0

Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model.


ABSTRACT: Somatic mutations in JAK2, MPL and Calreticulin and inflammation play a key role in pathophysiology of chronic myeloproliferative neoplasia (CMN). One of the most prominent cytokines elevated in serum of Polycythemia vera patients is interleukin-6 (IL-6). Currently, it is being discussed whether suppression of inflammation by anti-cytokine approaches as anti-IL-6 treatment may be therapeutically useful in CMN. We here sought to investigate the efficacy of anti-IL-6 treatment on inflammatory cytokines, hematocrit and splenomegaly in CMN like disease. JAK2-V617F knock-in mice (JAK2+/V617F) were treated for three weeks with anti-IL-6 antibody (Ab) or IgG-control. Upon anti-IL-6 Ab treatment, serum levels of CXCL2 and CXCL10 were significantly reduced. In addition, CXCL1, CCL11, M-CSF, G-CSF, IL-17, IL-12p40 and CCL2 were reduced by a factor of 0.3 -- 0.8. Partly, this was also achieved by applying high-dose IgG. Hematocrit, erythrocyte and leukocyte counts were elevated in JAK2+/V617F mice but were not reduced by anti-IL6 Ab treatment. In addition, there was no apparent amelioration of splenomegaly and spleen histopathology. In conclusion, anti-IL-6 Ab treatment did not result in improvement of hematological disease parameters but was shown to modulate the serum cytokine signature.

SUBMITTER: Baldauf CK 

PROVIDER: S-EPMC8791576 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2749451 | biostudies-literature
| S-EPMC7468352 | biostudies-literature
| S-EPMC6097748 | biostudies-literature
| S-EPMC3736166 | biostudies-other
| S-EPMC3325041 | biostudies-other
| S-EPMC4211877 | biostudies-literature
| S-EPMC4466074 | biostudies-literature
2014-08-29 | GSE47018 | GEO
| S-EPMC7534842 | biostudies-literature
| S-EPMC6688433 | biostudies-literature